Greener, more sustainable platforms for high-value recombinant protein production
Lead Research Organisation:
University of Kent
Department Name: Sch of Biosciences
Abstract
The greenerRPP project aims to markedly enhance the EU's capacity for the production of secreted high-quality recombinant
proteins, especially industrial enzymes and therapeutic proteins (biotherapeutics). The combined markets are in excess of $330 billion
p.a., and the products are of massive significance for healthcare and a sustainable bio-based economy. greenerRPP will address
urgent problems in these industries, such as difficult-to-express proteins and the rapidly-emerging issue of 'sustainability' in the
European biotechnology industry. It will deliver improvements in yield and process design that increase the industry's effectiveness
while simultaneously reducing high current levels of waste. It will deliver industrial enzymes that reduce energy and raw material
costs in countless industrial and domestic settings. To achieve this, we will develop powerful new microbial and mammalian cell
platforms that produce recombinant proteins in unusually high quantities and in unparalleled quality, and bring to market a suite of
super-producing platforms.
A comprehensive training programme will equip greenerRPP ESRs with the interdisciplinary and intersectoral skills required to be
future leaders in these industries, while emphasising sustainability and gender-diversity dimension principles at every level. Finally,
the programme addresses the stark global inequality in this biotechnology sector: recombinant protein production is largely carried
out in (or outsourced by) high-income countries, placing low/middle income countries at a massive disadvantage. greenerRPP
includes a series of South East Asian Institutions as Associated Partners, to develop a global network with a knowledge exchangesecondment
programme that boosts these countries' own manufacturing programmes. greenerRPP ESRs will thus enhance a
European industrial sector that has never been more important to society, while making it 'greener' and reaching out to lower income
countries.
proteins, especially industrial enzymes and therapeutic proteins (biotherapeutics). The combined markets are in excess of $330 billion
p.a., and the products are of massive significance for healthcare and a sustainable bio-based economy. greenerRPP will address
urgent problems in these industries, such as difficult-to-express proteins and the rapidly-emerging issue of 'sustainability' in the
European biotechnology industry. It will deliver improvements in yield and process design that increase the industry's effectiveness
while simultaneously reducing high current levels of waste. It will deliver industrial enzymes that reduce energy and raw material
costs in countless industrial and domestic settings. To achieve this, we will develop powerful new microbial and mammalian cell
platforms that produce recombinant proteins in unusually high quantities and in unparalleled quality, and bring to market a suite of
super-producing platforms.
A comprehensive training programme will equip greenerRPP ESRs with the interdisciplinary and intersectoral skills required to be
future leaders in these industries, while emphasising sustainability and gender-diversity dimension principles at every level. Finally,
the programme addresses the stark global inequality in this biotechnology sector: recombinant protein production is largely carried
out in (or outsourced by) high-income countries, placing low/middle income countries at a massive disadvantage. greenerRPP
includes a series of South East Asian Institutions as Associated Partners, to develop a global network with a knowledge exchangesecondment
programme that boosts these countries' own manufacturing programmes. greenerRPP ESRs will thus enhance a
European industrial sector that has never been more important to society, while making it 'greener' and reaching out to lower income
countries.
Organisations
People |
ORCID iD |
| Colin Robinson (Principal Investigator) |